Press Releases


Alkermes Announces First Quarter Fiscal 2008 Results

-- Company Reports Record Quarterly Revenues, with 34% Increase in Total Revenues Compared to First Quarter Fiscal 2007 --

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. today announced financial results for its first quarter of fiscal 2008. Financial highlights for the quarter ended June 30, 2007 include:

  • Fourth consecutive profitable quarter on a GAAP basis, with net income of $8.7 million.
  • Record quarterly revenues of $68.9 million. Worldwide sales of RISPERDAL® CONSTA® by Janssen-Cilag (Janssen) were $278.7 million.
  • Strong balance sheet, with cash and total investments of $330.9 million.

Key operating results for the first quarter of fiscal 2008 include the following:

  • Net income was $8.7 million or a basic earnings per share of $0.09 and a diluted earnings per share of $0.08, including $5.7 million in share-based compensation expense, compared to a net loss of $0.7 million or a basic and diluted loss per share of $0.01, which included $8.3 million in share-based compensation expense, for the same period in 2006.
  • Pro forma net income was $14.3 million or a basic and diluted earnings per share of $0.14, compared to a net income of $6.8 million or a basic and diluted earnings per share of $0.07, for the same period in 2006.

Alkermes is providing pro forma results as a complement to GAAP results. The pro forma net income excludes certain noncash or nonrecurring items, and Alkermes' management believes these pro forma measures help to indicate underlying trends in the company's ongoing operations. The reconciliation between pro forma and reported diluted earnings or loss per share for the first quarters of fiscal 2008 and 2007 is provided in the following table:

                                                           Reported
                                                            GAAP
                             Share-Based   Net Change in    Diluted
         Pro Forma Diluted    Compensation  Fair Value of   Earnings
          Earnings            Expense       Warrants        or Loss
---------------------------------------------------------------------
Q1
FY 2008              $ 0.14        ($0.06)             --  $   0.08
---------------------------------------------------------------------
Q1
FY 2007              $ 0.07        ($0.08)         $ 0.01    ($0.01)
---------------------------------------------------------------------

Note: Amounts may not sum due to rounding.

"Our financial results this quarter were strong, reflecting the continued success of RISPERDAL CONSTA in the marketplace and increased research and development revenues from our partnered programs," stated James Frates, chief financial officer of Alkermes.

The following financial results are reported on a GAAP basis and include share-based compensation expense:

Revenues

  • Total revenues for the quarter ended June 30, 2007 were $68.9 million, compared to $51.5 million for the same period in 2006.
  • Total manufacturing revenues for the quarter ended June 30, 2007 were $31.5 million, consisting of $30.2 million for RISPERDAL CONSTA and $1.3 million for VIVITROL®, compared to $22.2 million for the same period in 2006, consisting of $19.1 million for RISPERDAL CONSTA and $3.1 million for VIVITROL.
  • Royalty revenues for the quarter ended June 30, 2007 were $7.0 million based on RISPERDAL CONSTA sales of $278.7 million, compared to $5.1 million based on RISPERDAL CONSTA sales of $205.2 million for the same period in 2006.
  • Research and development (R&D) revenue under collaborative arrangements for the quarter ended June 30, 2007 was $23.4 million, compared to $14.5 million for the same period in 2006.
  • Net collaborative profit for the quarter ended June 30, 2007 was $7.0 million, compared to $9.7 million for the same period in 2006.

Costs and Expenses

  • Cost of goods manufactured for the quarter ended June 30, 2007 was $10.1 million, of which $9.0 million related to RISPERDAL CONSTA and $1.1 million related to VIVITROL, compared to $9.3 million for the same period in 2006, of which $6.5 million related to RISPERDAL CONSTA and $2.8 million related to VIVITROL.
  • R&D expenses for the quarter ended June 30, 2007 were $32.6 million compared to $25.9 million for the same period in 2006.
  • Selling, general and administrative (SG&A) expenses for the quarter ended June 30, 2007 were $15.4 million compared to $16.5 million for the same period in 2006.
  • Interest income for the quarter ended June 30, 2007 was $4.4 million compared to $4.3 million for the same period in 2006. Interest expense for the quarter ended June 30, 2007 was $4.1 million compared to $5.5 million for the same period in 2006.
  • Share-based compensation expense (included in the expenses above) for the quarter ended June 30, 2007 was $5.7 million, of which $0.6 million related to cost of goods manufactured, $1.8 million related to R&D expenses, and $3.3 million related to SG&A expenses. Share-based compensation expense for the quarter ended June 30, 2006 was $8.3 million, of which $0.3 million related to cost of goods manufactured, $2.8 million related to R&D expenses, and $5.2 million related to SG&A expenses.
  • Income tax expense for the quarter ended June 30, 2007 was $2.4 million, compared to $0.2 million for the same period in 2006.

At June 30, 2007, Alkermes had cash and total investments of $330.9 million, compared to $356.7 million at March 31, 2007.

Recent Highlights

  • Positive results from phase 1/2 study of ALKS 29: Alkermes announced positive preliminary results from a phase 1/2 clinical trial of ALKS 29 in alcohol dependent patients. In the study, ALKS 29 was generally well tolerated and led to a statistically significant improvement compared to placebo in terms of percent of days abstinent, percent of heavy drinking days and average number of drinks per day. ALKS 29 is a combination of two agents with distinct pharmacologic properties designed to provide advantages over current oral medications for the treatment of alcohol dependence.
  • Initiation of a phase 1 study of AIR® PTH: Alkermes and its partner Eli Lilly and Company (Lilly) initiated a phase 1 clinical study of AIR® parathyroid hormone (AIR PTH (1-34)) in healthy volunteers. The phase 1 study will assess the safety, tolerability and pharmacokinetics of AIR PTH in healthy postmenopausal women. Alkermes and Lilly expect to report top-line results from the study by early 2008.

Conference Call

Alkermes will host a conference call at 4:30 p.m. EDT on Thursday, August 2, 2007 to discuss these financial results and provide an update on the company. The conference call may be accessed by dialing 1-866-835-8825 for domestic callers and 1-703-639-1407 for international callers. The conference call ID number is 1119053. In addition, a replay of the conference call will be available from 7:30 p.m. EDT on Thursday, August 2, 2007 through 5:00 p.m. EDT on Tuesday, August 7, 2007, and may be accessed by visiting Alkermes' website or by dialing 1-888-266-2081 for domestic callers and 1-703-925-2533 for international callers. The replay access code is 1119053. Alkermes is also providing a podcast MP3 file available for download on the Alkermes website, which will be available shortly following the conference call and will be available until Tuesday, August 7, 2007.

About Alkermes

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL® CONSTA® ((risperidone) long-acting injection), the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag (Janssen), a wholly owned division of Johnson & Johnson; and VIVITROL® (naltrexone for extended-release injectable suspension) the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes. Alkermes' headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to: statements concerning future business and operating results and profitability; the therapeutic value of the company's product candidates to patients; plans for clinical trials; expectations concerning the commercialization of RISPERDAL CONSTA and VIVITROL; the successful supply of RISPERDAL CONSTA and VIVITROL; and the successful continuation of development activities for proprietary and partnered programs, including ALKS 29 and AIR PTH. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and the company's business is subject to significant risk and uncertainties and there can be no assurance that its actual results will not differ materially from its expectations. These risks and uncertainties include, among others: whether the company can continue to successfully manufacture RISPERDAL CONSTA and VIVITROL at a commercial scale or economically or in sufficient quantities to supply the market; whether RISPERDAL CONSTA will continue to be commercialized successfully by its partner Janssen and whether VIVITROL will be commercialized successfully by Alkermes and its partner Cephalon; whether ALKS 29 will provide advantages over existing oral medications; whether Alkermes and Lilly will report top-line results from the study of AIR PTH by early 2008; whether advancement of the company's proprietary and partnered product candidates, including ALKS 29 and AIR PTH, will be delayed due to actions or decisions by its partners with regard to development and regulatory strategy, timing and funding which are out of its control, and the outcome of clinical and preclinical work the company is pursuing, both on its own and with partners; decisions by the FDA or foreign regulatory authorities regarding the company's product candidates; potential changes in cost, scope and duration of clinical trials; and whether RISPERDAL CONSTA, VIVITROL and the company's product candidates, in commercial use, have unintended side effects, adverse reactions or incidents of misuse that could cause the FDA or other health authorities to require post approval studies or require removal of its products from the market. For further information with respect to factors that could cause the company's actual results to differ materially from expectations, reference is made to the reports the company filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements made in this release are made only as of the date hereof and the company disclaims any intention or responsibility for updating predictions or financial expectations contained in this release.

AIR® is a registered trademark of Alkermes, Inc.; VIVITROL® is a registered trademark of Cephalon, Inc.; RISPERDAL® CONSTA® is a registered trademark of Janssen-Cilag.

Alkermes, Inc. and Subsidiaries
Selected Financial Information (Unaudited)

                                                     Three     Three
                                                      Months   Months
                                                      Ended    Ended
Condensed Consolidated Statements of Operations     June 30,  June 30,
(In thousands, except per share data)                   2007     2006
----------------------------------------------------------------------
Revenues:
  Manufacturing revenues                            $ 31,517  $22,193
  Royalty revenues                                     6,982    5,139
  Research and development revenue under
   collaborative arrangements                         23,450   14,464
  Net collaborative profit                             6,989    9,742
----------------------------------------------------------------------
    Total Revenues                                    68,938   51,538
----------------------------------------------------------------------
Expenses:
  Cost of goods manufactured                          10,145    9,338
  Research and development                            32,619   25,863
  Selling, general and administrative                 15,400   16,530
----------------------------------------------------------------------
    Total Expenses                                    58,164   51,731
----------------------------------------------------------------------
Operating Income (Loss)                               10,774     (193)
----------------------------------------------------------------------
Other Income (Expense):
  Interest income                                      4,402    4,335
  Interest expense                                    (4,073)  (5,473)
  Other income (expense), net                             26      787
----------------------------------------------------------------------
    Total Other Income (Expense)                         355     (351)
----------------------------------------------------------------------
Income (Loss) before Income Taxes                     11,129     (544)
----------------------------------------------------------------------
Income taxes                                           2,382      171
----------------------------------------------------------------------
Net Income (Loss)                                   $  8,747    ($715)
----------------------------------------------------------------------

Earnings (Loss) per Common Share:
  Basic                                             $   0.09   ($0.01)
----------------------------------------------------------------------
  Diluted                                           $   0.08   ($0.01)
----------------------------------------------------------------------

Weighted Average Number of Common Shares
 Outstanding (GAAP and Pro Forma):
  Basic                                              101,324   93,784
----------------------------------------------------------------------
  Diluted                                            104,191   99,754
----------------------------------------------------------------------

Pro Forma Reconciliation:
Net Income - GAAP                                   $  8,747    ($715)
  Share-based compensation expense                     5,747    8,347
  Net increase in the fair value of warrants            (196)    (846)
----------------------------------------------------------------------
Net Income - Pro Forma                              $ 14,298  $ 6,786
----------------------------------------------------------------------

Pro Forma Earnings per Common Share:
  Basic                                             $   0.14  $  0.07
----------------------------------------------------------------------
  Diluted                                           $   0.14  $  0.07
----------------------------------------------------------------------
Condensed Consolidated Balance Sheets      June 30,    March 31,
(In thousands)                                 2007            2007
-------------------------------------------------------------------
Cash, cash equivalents and total
 investments                               $330,896        $356,726
Receivables                                  66,782          56,049
Prepaid expenses and other current assets     9,063           7,054
Inventory                                    20,218          18,190
Property, plant and equipment, net          130,263         123,595
Other assets                                  7,036           7,007
-------------------------------------------------------------------
Total Assets                               $564,258        $568,621
-------------------------------------------------------------------
Unearned milestone revenue - current
 portion                                   $  6,333        $ 11,450
Other current liabilities                    31,177          50,610
Non-recourse RISPERDAL CONSTA secured 7%
 notes                                      157,694         156,851
Unearned milestone revenue - long-term
 portion                                    115,738         117,300
Deferred revenue - long-term portion         23,747          22,153
Other long-term liabilities                   6,650           6,796
Total shareholders' equity                  222,919         203,461
-------------------------------------------------------------------
Total Liabilities and Shareholders' Equity $564,258        $568,621
-------------------------------------------------------------------
This selected financial information should be read in conjunction with
 the consolidated financial statements and notes thereto included in
 the company's Annual Report on Form 10-K for the year ended March 31,
 2007, and the company's report on Form 10-Q for the three months
 ended June 30, 2007, which the company intends to file in August
 2007.
VIVITROL(R) Selected Financial Information      Three
                                                 Months
----------------------------------------------
                                                 Ended
  (Unaudited, in thousands)                    June 30,   Cumulative
                                                   2007  Collaboration
                                               --------- -------------
  VIVITROL Income Statement
  Alkermes' expenses                           $  5,680     $  56,901
  Cephalon's net losses                          19,083        87,207

                                               --------- -------------
  VIVITROL net losses                          $ 24,763     $ 144,108
                                               --------- -------------


  Flow of funds
     Alkermes paid Cephalon: net losses up to
      the $124.6M net loss cap (1)              ($5,223)     ($73,347)
     Cephalon paid Alkermes: Alkermes'
      expenses in excess of the net loss cap      5,647         5,647

                                               --------- -------------
  Net flow of funds from (to) Cephalon (3)     $    424      ($67,700)
                                               --------- -------------


  Net Collaborative Profit
     Milestone revenue recognized to offset
      losses up to the net loss cap (1)        $  5,256     $ 144,493
     Milestone revenue recognized with respect
      to the license (2)                          1,309         6,396
     Net flow of funds from (to) Cephalon (3)       424       (67,700)

                                               --------- -------------
  Net collaborative profit                     $  6,989     $  83,189
                                               ========= =============



Notes -----

(1)Expenses incurred on behalf of the collaboration by Alkermes, Inc. ("Alkermes") and net losses incurred on behalf of the collaboration by Cephalon, Inc. ("Cephalon") contribute to the cumulative net product losses incurred on VIVITROL.
Alkermes was responsible for the first $124.6 million of these cumulative net product losses (the "net loss cap").
Alkermes recognized milestone revenue to offset the net product losses incurred up to the net loss cap.
The collaboration reached the net loss cap in April 2007, at which point the recognition of milestone revenue related to this accounting unit stopped.
In addition, in prior periods, Alkermes recognized $19.9 million of milestone revenue to offset expenses it incurred for which it was solely responsible, related to the successful FDA approval of VIVITROL and the successful completion of the first VIVITROL manufacturing line. These $19.9 million of expenses did not contribute to the cumulative net product losses.

(2)Milestone revenue related to the license commenced upon approval of VIVITROL, by the FDA, on April 13, 2006 and is being recognized on a straight line basis over 10 years, at the rate of approximately $1.3 million per quarter.

(3)Alkermes was responsible for net losses up to the net loss cap and reimbursed Cephalon for their net losses during this period. Once the net loss cap was reached in April 2007, Cephalon started to reimburse Alkermes for its VIVITROL expenses. This will continue through December 31, 2007, after which the two companies will share any net profits or losses.

Through June 30, 2007, Alkermes has recognized $152.5 million of milestone revenue out of the $274.6 million received from Cephalon. In addition to (1) and (2) above, this recognition includes $1.6 million of milestone revenue related to a 10% mark-up on manufacturing revenue, which is reported by Alkermes within manufacturing revenues in the unaudited condensed consolidated statement of operations.

Contact:

James Frates
Chief Financial Officer Alkermes, Inc.
(617) 494-0171
or
Rebecca Peterson
Vice President, Corporate Communications Alkermes, Inc.
(617) 583-6378